Max Planck Society Ends Elsevier Subscription

The move is a show of support for Project DEAL and the open-access movement.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: Max Planck Institute for Biophysics
© ISTOCK.COM, OLLO

The Max Planck Society, an enormous German research organization 14,000 scientists strong and comprising multiple research institutes, has ended its subscription to Elsevier journals, the organization announced in a statement this Tuesday (December 18). It did so in support of the German open-access initiative called Project DEAL, after unsuccessful attempts to negotiate an open-access agreement with the publisher. The organization’s digital library will no longer have access to Elsevier’s approximately 2,500 journals, including The Lancet and Cell, once the subscription expires on December 31.

“The system of scholarly publishing today is a relic of the print era, and we want to activate a real paradigm shift in order to finally utilise the opportunities of the digital age,” says Gerard Meijer, director of the Max Planck Society’s (MPS) Fritz Haber Institute and a member of the DEAL negotiating team, in the statement.

Project ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Ashley P. Taylor

    This person does not yet have a bio.
Share
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Artificial Inc. Logo

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development